Cost Per-Responder Analysis of Secukinumab Compared To Adalimumab For The Treatmenmt of Ankylosing Spondylitis Over One Year In Saudi Arabia

Autor:	N Alshehri, H Al Mudaiheem, L Al Kateb, N Zakaria, K Al Jufan, M Al Howimel, H Al Hamdan, G Ramakrishna, A AlAlwan
Rok vydání:	2018
Předmět:	Ankylosing spondylitis medicine.medical_specialty business.industry Health Policy Internal medicine Public Health Environmental and Occupational Health medicine Adalimumab Secukinumab medicine.disease business medicine.drug
Zdroj:	Value in Health. 21:S81-S82
ISSN:	1098-3015
DOI:	10.1016/j.jval.2018.07.609
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0fedf7adc1dc72cc5b72b488282f5bcd https://doi.org/10.1016/j.jval.2018.07.609 Zobrazit plný text záznamu Full Text from ScienceDirect